Research programme: hepatitis C NS4 protein inhibitors - Eiger Biopharmaceuticals

Drug Profile

Research programme: hepatitis C NS4 protein inhibitors - Eiger Biopharmaceuticals

Alternative Names: 4BAH2 inhibitors; NS4B-RNA inhibitors

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Eiger BioPharmaceuticals
  • Developer Eiger BioPharmaceuticals, Inc.
  • Class Benzimidazoles; Indazoles; Small molecules
  • Mechanism of Action Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in USA
  • 22 Mar 2016 Celladon has merged with Eiger BioPharmaceuticals and the combined company is now called Eiger BioPharmaceuticals, Inc.
  • 04 Aug 2009 Eiger BioPharmaceuticals enters into a technology licensing agreement with Stanford University
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top